OBJECTIVES: The aim of this study was to use multidetector computed tomography (MDCT) to assess therapeutic effects of myocardial regenerative cell therapies. BACKGROUND: Cell transplantation is being widely investigated as a potential therapy in heart failure. Noninvasive imaging techniques are frequently used to investigate therapeutic effects of cell therapies in the preclinical and clinical settings. Previous studies have shown that cardiac MDCT can accurately quantify myocardial scar tissue and determine left ventricular (LV) volumes and ejection fraction (LVEF). METHODS: Twenty-two minipigs were randomized to intramyocardial injection of phosphate-buffered saline (placebo, n = 9) or 200 million mesenchymal stem cells (MSC, n = 13) 12 weeks after myocardial infarction (MI). Cardiac magnetic resonance and MDCT acquisitions were performed before randomization (12 weeks after MI induction) and at the study endpoint 24 weeks after MI induction. None of the animals received medication to control the intrinsic heart rate during first-pass acquisitions for assessment of LV volumes and LVEF. Delayed-enhancement MDCT imaging was performed 10 min after contrast delivery. Two blinded observers analyzed MDCT acquisitions. RESULTS: MDCT demonstrated that MSC therapy resulted in a reduction of infarct size from 14.3 ± 1.2% to 10.3 ± 1.5% of LV mass (p = 0.005), whereas infarct size increased in nontreated animals (from 13.8 ± 1.3% to 16.5 ± 1.5%; p = 0.02) (placebo vs. MSC; p = 0.003). Both observers had excellent agreement for infarct size (r = 0.96; p < 0.001). LVEF increased from 32.6 ± 2.2% to 36.9 ± 2.7% in MSC-treated animals (p = 0.03) and decreased in placebo animals (from 33.3 ± 1.4% to 29.1 ± 1.5%; p = 0.01; at week 24: placebo vs. MSC; p = 0.02). Infarct size, end-diastolic LV volume, and LVEF assessed by MDCT compared favorably with those assessed by cardiac magnetic resonance acquisitions (r = 0.70, r = 0.82, and r = 0.902, respectively; p < 0.001). CONCLUSIONS: This study demonstrated that cardiac MDCT can be used to evaluate infarct size, LV volumes, and LVEF after intramyocardial-delivered MSC therapy. These findings support the use of cardiac MDCT in preclinical and clinical studies for novel myocardial therapies.
OBJECTIVES: The aim of this study was to use multidetector computed tomography (MDCT) to assess therapeutic effects of myocardial regenerative cell therapies. BACKGROUND: Cell transplantation is being widely investigated as a potential therapy in heart failure. Noninvasive imaging techniques are frequently used to investigate therapeutic effects of cell therapies in the preclinical and clinical settings. Previous studies have shown that cardiac MDCT can accurately quantify myocardial scar tissue and determine left ventricular (LV) volumes and ejection fraction (LVEF). METHODS: Twenty-two minipigs were randomized to intramyocardial injection of phosphate-buffered saline (placebo, n = 9) or 200 million mesenchymal stem cells (MSC, n = 13) 12 weeks after myocardial infarction (MI). Cardiac magnetic resonance and MDCT acquisitions were performed before randomization (12 weeks after MI induction) and at the study endpoint 24 weeks after MI induction. None of the animals received medication to control the intrinsic heart rate during first-pass acquisitions for assessment of LV volumes and LVEF. Delayed-enhancement MDCT imaging was performed 10 min after contrast delivery. Two blinded observers analyzed MDCT acquisitions. RESULTS: MDCT demonstrated that MSC therapy resulted in a reduction of infarct size from 14.3 ± 1.2% to 10.3 ± 1.5% of LV mass (p = 0.005), whereas infarct size increased in nontreated animals (from 13.8 ± 1.3% to 16.5 ± 1.5%; p = 0.02) (placebo vs. MSC; p = 0.003). Both observers had excellent agreement for infarct size (r = 0.96; p < 0.001). LVEF increased from 32.6 ± 2.2% to 36.9 ± 2.7% in MSC-treated animals (p = 0.03) and decreased in placebo animals (from 33.3 ± 1.4% to 29.1 ± 1.5%; p = 0.01; at week 24: placebo vs. MSC; p = 0.02). Infarct size, end-diastolic LV volume, and LVEF assessed by MDCT compared favorably with those assessed by cardiac magnetic resonance acquisitions (r = 0.70, r = 0.82, and r = 0.902, respectively; p < 0.001). CONCLUSIONS: This study demonstrated that cardiac MDCT can be used to evaluate infarct size, LV volumes, and LVEF after intramyocardial-delivered MSC therapy. These findings support the use of cardiac MDCT in preclinical and clinical studies for novel myocardial therapies.
Authors: Albert C Lardo; Marco A S Cordeiro; Caterina Silva; Luciano C Amado; Richard T George; Anastasios P Saliaris; Karl H Schuleri; Veronica R Fernandes; Menekhem Zviman; Saman Nazarian; Henry R Halperin; Katherine C Wu; Joshua M Hare; Joao A C Lima Journal: Circulation Date: 2006-01-24 Impact factor: 29.690
Authors: M B Britten; N D Abolmaali; B Assmus; R Lehmann; J Honold; J Schmitt; T J Vogl; H Martin; V Schächinger; S Dimmeler; A M Zeiher Journal: Circulation Date: 2003-10-13 Impact factor: 29.690
Authors: David Bello; Dipan J Shah; George M Farah; Silvia Di Luzio; Michele Parker; Maryl R Johnson; William G Cotts; Francis J Klocke; Robert O Bonow; Robert M Judd; Mihai Gheorghiade; Raymond J Kim Journal: Circulation Date: 2003-10-13 Impact factor: 29.690
Authors: Andreas H Mahnken; Philipp Bruners; Christoph M Bornikoel; Thomas Flohr; Bernhard Schmidt; Markus Völk; Gabriele A Krombach; Rolf W Guenther; Georg Mühlenbruch Journal: Eur J Radiol Date: 2009-08-25 Impact factor: 3.528
Authors: Frank M Bengel; Richard T George; Karl H Schuleri; Albert C Lardo; Kai C Wollert Journal: Eur Heart J Cardiovasc Imaging Date: 2013-05-29 Impact factor: 6.875
Authors: Viky Y Suncion; Eduard Ghersin; Joel E Fishman; Juan Pablo Zambrano; Vasileios Karantalis; Nicole Mandel; Katarina H Nelson; Gary Gerstenblith; Darcy L DiFede Velazquez; Elayne Breton; Kranthi Sitammagari; Ivonne H Schulman; Sabrina N Taldone; Adam R Williams; Cristina Sanina; Peter V Johnston; Jeffrey Brinker; Peter Altman; Muzammil Mushtaq; Barry Trachtenberg; Adam M Mendizabal; Melissa Tracy; Jose Da Silva; Ian K McNiece; Alberto C Lardo; Richard T George; Joshua M Hare; Alan W Heldman Journal: Circ Res Date: 2014-01-21 Impact factor: 17.367
Authors: Miikka Tarkia; Christoffer Stark; Matti Haavisto; Rasmus Kentala; Tommi Vähäsilta; Timo Savunen; Marjatta Strandberg; Ville-Veikko Hynninen; Virva Saunavaara; Tuula Tolvanen; Mika Teräs; Johanna Rokka; Mikko Pietilä; Pekka Saukko; Anne Roivainen; Antti Saraste; Juhani Knuuti Journal: J Nucl Cardiol Date: 2015-02-20 Impact factor: 5.952
Authors: Zhiyu Ling; John McManigle; Vadim Zipunnikov; Farhad Pashakhanloo; Irfan M Khurram; Stefan L Zimmerman; Binu Philips; Joseph E Marine; David D Spragg; Hiroshi Ashikaga; Hugh Calkins; Saman Nazarian Journal: Heart Rhythm Date: 2015-01-13 Impact factor: 6.343
Authors: Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare Journal: JAMA Date: 2014-01-01 Impact factor: 56.272